← Back to Clinical Trials
Recruiting NCT05205954

NCT05205954 HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05205954
Status Recruiting
Phase
Sponsor Massachusetts General Hospital
Condition Cirrhosis
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2025-07-21
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Hepatology Home Hospital

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2025-07-21 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This research study is evaluating a program that entails a healthcare at home intervention for people with advanced liver disease.

Eligibility Criteria

Inclusion Criteria: 1. Adult patients ≥ 18 years old with diagnosis of cirrhosis based on histology, radiology, and/or elastography presenting to the emergency department or inpatient general medicine service 2. Patients must have one of the following: 1. Ascites (requiring diuretics or serial large volume paracenteses) 2. Hepatic hydrothorax (requiring diuretics) 3. Hepatic encephalopathy (requiring medications) Exclusion Criteria: All existing MGB home hospital criteria apply, with the following taking precedent for this specific condition 1. History of solid organ transplantation 2. On hemodialysis 3. MELD score \> 20 4. Score \<10 on Simplified Animal Naming Test (S-ANT1) 5. Current admission for hemodynamically significant GI bleeding or alcohol withdrawal 6. Require routine administration of controlled substances 7. Those deemed ineligible based on the MGH Home Hospital, inpatient medicine or hepatology clinician evaluation

Contact & Investigator

Central Contact

Nneka Ufere, MD, MSCE

✉ nufere@partners.org

📞 617-643-3408

Frequently Asked Questions

Who can join the NCT05205954 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cirrhosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05205954 currently recruiting?

Yes, NCT05205954 is actively recruiting participants. Contact the research team at nufere@partners.org for enrollment information.

Where is the NCT05205954 trial being conducted?

This trial is being conducted at Boston, United States, Boston, United States.

Who is sponsoring the NCT05205954 clinical trial?

NCT05205954 is sponsored by Massachusetts General Hospital. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology